Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.
- Published in:
- Therapeutic Advances in Hematology, 2016, v. 7, n. 4, p. 179, doi. 10.1177/2040620716654102
- By:
- Publication type:
- Article
Works matching IS 20406207 AND DT 2016 AND VI 7 AND IP 4
Results: 6
1
2
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.
- Published in:
- Therapeutic Advances in Hematology, 2016, v. 7, n. 4, p. 187, doi. 10.1177/2040620716652862
- By:
- Publication type:
- Article
3
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma.
- Published in:
- Therapeutic Advances in Hematology, 2016, v. 7, n. 4, p. 209, doi. 10.1177/2040620716652861
- By:
- Publication type:
- Article
4
Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data.
- Published in:
- Therapeutic Advances in Hematology, 2016, v. 7, n. 4, p. 222, doi. 10.1177/2040620716648567
- By:
- Publication type:
- Article
5
Bortezomib for the treatment of mantle cell lymphoma: an update.
- Published in:
- Therapeutic Advances in Hematology, 2016, v. 7, n. 4, p. 196, doi. 10.1177/2040620716648566
- By:
- Publication type:
- Article
6
Unusual, spontaneous aneurysm formation in a patient being treated with ibrutinib for chronic lymphocytic leukemia.
- Published in:
- 2016
- By:
- Publication type:
- Letter